GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexeo Therapeutics Inc (NAS:LXEO) » Definitions » Asset Turnover

Lexeo Therapeutics (Lexeo Therapeutics) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Lexeo Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Lexeo Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Lexeo Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $176.51 Mil. Therefore, Lexeo Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Lexeo Therapeutics's annualized ROE % for the quarter that ended in Mar. 2024 was -58.50%. It is also linked to ROA % through Du Pont Formula. Lexeo Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -49.14%.


Lexeo Therapeutics Asset Turnover Historical Data

The historical data trend for Lexeo Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexeo Therapeutics Asset Turnover Chart

Lexeo Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Asset Turnover
0.02 0.02 0.01 -

Lexeo Therapeutics Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lexeo Therapeutics's Asset Turnover

For the Biotechnology subindustry, Lexeo Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexeo Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Lexeo Therapeutics's Asset Turnover falls into.



Lexeo Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Lexeo Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (97.076+139.807)/ 2 )
=0/118.4415
=0.00

Lexeo Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (139.807+213.205)/ 2 )
=0/176.506
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Lexeo Therapeutics  (NAS:LXEO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Lexeo Therapeutics's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-86.728/148.2425
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-86.728 / 0)*(0 / 176.506)*(176.506/ 148.2425)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.1907
=ROA %*Equity Multiplier
=-49.14 %*1.1907
=-58.50 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Lexeo Therapeutics's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-86.728/176.506
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-86.728 / 0)*(0 / 176.506)
=Net Margin %*Asset Turnover
= %*0
=-49.14 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Lexeo Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Lexeo Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexeo Therapeutics (Lexeo Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
345 Park Avenue South, Floor 6, New York, NY, USA, 10010
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
Executives
Lundbeckfond Invest A/s 10 percent owner SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Longitude Capital Partners Iv, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Omega Fund Vi Gp, L.p. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Omega Fund Vi, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Richard Nolan Townsend director, officer: Chief Executive Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Jenny Robertson officer: Chief Legal and Admin. Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Paul Mccormac officer: Chief Technical Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Bernard Davitian director C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Eric Adler officer: Chief Scientific Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Brenda Cooperstone director C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Longitude Venture Partners Iv, L.p. 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Omega Fund Vi Gp Manager, Ltd. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Paula H Cholmondeley director 221 W PHILADELPHIA ST, SUITE 60W, YORK PA 17401-2991
Reinaldo M Diaz director C/O DIAZ & ALTSCHUL CAPITAL, 950 THIRD AVE, NEW YORK NY 10022
Mette Kirstine Agger director C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830

Lexeo Therapeutics (Lexeo Therapeutics) Headlines